Bruceine D shows potential to overcome EGFR-TKI resistance in lung adenocarcinoma
Bruceine D epigenetically restores SMAD3 expression and suppresses malignant progression in EGFR-TKI-resistant lung adenocarcinoma.
Asset / Drug
Drug and asset intelligence for Bruceine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.